* blood pressure \< 90/60mm hg * respiratory rate ≥ 30/min * known cardiac condition * known g6pd deficiency * patients with \< 45kg * egfr \< 30 ml/min or alt ≥ 3n or body temperature ≥ 38°c or any life-threatening comorbidity * any reason that makes it impossible to monitor the patient during the study period * baseline ecg prior to randomization showing qtc \> 500 ms * ongoing treatment other than symptomatic * history of retinopathy * absolute contra-indication to treatment with hydroxychloroquine (known hypersensitivity, concomitant treatment at risk of torsades de pointes) * contraindication to any study medication including allergy * ongoing treatment with high dose systemic chronic corticosteroid (\> 40 mg) * patients treated by immunosuppressants treatment at the time of randomization * known pregnant women and breastfeeding women

* blood pressure \< 90/60mm hg * respiratory rate ≥ 30/min * known cardiac condition * known g6pd deficiency * patients with \< 45kg * egfr \< 30 ml/min or alt ≥ 3n or body temperature ≥ 38°c or any life-threatening comorbidity * any reason that makes it impossible to monitor the patient during the study period * baseline ecg prior to randomization showing qtc \> 500 ms * ongoing treatment other than symptomatic * history of retinopathy * absolute contra-indication to treatment with hydroxychloroquine (known hypersensitivity, concomitant treatment at risk of torsades de pointes) * contraindication to any study medication including allergy * ongoing treatment with high dose systemic chronic corticosteroid (\> 40 mg) * patients treated by immunosuppressants treatment at the time of randomization * known pregnant women and breastfeeding women

- blood pressure < 90/60mm hg - respiratory rate ≥ 30/min - known cardiac condition - known g6pd deficiency - patients with < 45kg - egfr < 30 ml/min or alt ≥ 3n or body temperature ≥ 38°c or any life-threatening comorbidity - any reason that makes it impossible to monitor the patient during the study period - baseline ecg prior to randomization showing qtc > 500 ms - ongoing treatment other than symptomatic - history of retinopathy - absolute contra-indication to treatment with hydroxychloroquine (known hypersensitivity, concomitant treatment at risk of torsades de pointes) - contraindication to any study medication including allergy - ongoing treatment with high dose systemic chronic corticosteroid (> 40 mg) - patients treated by immunosuppressants treatment at the time of randomization - known pregnant women and breastfeeding women

- blood pressure < 90/60mm hg - respiratory rate ≥ 30/min - known cardiac condition - known g6pd deficiency - patients with < 45kg - egfr < 30 ml/min or alt ≥ 3n or body temperature ≥ 38°c or any life-threatening comorbidity - any reason that makes it impossible to monitor the patient during the study period - baseline ecg prior to randomization showing qtc > 500 ms - ongoing treatment other than symptomatic - history of retinopathy - absolute contra-indication to treatment with hydroxychloroquine (known hypersensitivity, concomitant treatment at risk of torsades de pointes) - contraindication to any study medication including allergy - ongoing treatment with high dose systemic chronic corticosteroid (> 40 mg) - patients treated by immunosuppressants treatment at the time of randomization - known pregnant women and breastfeeding women